Trial Profile

A clinical trial evaluating Tislelizumab and Decoy20

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2025 According to an Indaptus Therapeutics Media Release, the company look forward to generating additional data in the months ahead as it prepare to initiate planned combination trial with BeiGene's PD-1 inhibitor, tislelizumab and plans to dose the first patients in its combination study.
14 Nov 2024 New trial record
11 Nov 2024 According to Indaptus Therapeutics Media Release, company plans to roll out its trial combining Decoy20 with tislelizumab (BeiGene) next year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com